Pneumonia threatens patient's life seriously in MRSA courtyard It is very urgent to treat in time

Pneumonia threatens patient's life seriously in MRSA courtyard It is very urgent to treat in time
News from Beijing on December 8 of www.people.com.cn (Reporter Chen YeFei) Able to bear golden yellow staphylococcus (MRSA) of west forest of first oxygen Infect and nearly spread all over the whole world from finding to the present, become one of the important pathogens infected in the courtyard. In the face of MRSA detection rate obvious ascendant trend and increasing number of the infected and high mortality arising from this appearing in recent years, " infect and make a diagnosis and give treatment the new development of the tactics in MRSA courtyard " The meeting was held in Beijing a few days ago, nearly 120 Chinese and foreign expert canvass positive effective experience therapeutic method in order to tackle MRSA, infect to the intersection of patient and serious threat becoming that life lead to the fact together while being participating in the conference.
The Deputy Director of department of medial science of the New York State University of U.S.A., hospital of U.S.A. Thorpe Wen university cure the head of the department Niederman professor to point out at the meeting: Pneumonia is a kind of important disease all the time in MRSA courtyard, because there can seldom be effects and is able to bear bacterial strain of medicine to this kind of in the existing antibacterial medicine, so the treatment chooses more limitedly. Resist infection clinically and treat the challenge that faces to increase constantly, it is the key to reducing patient's mortality to control and infect effectively fast. So, once suspect the impatient results from able to bear the bacterial strain of medicine and infecting to generates heat, the experience antibacterial treatment is very urgent. Choose the antibacterial medicine rationally, launch the experience antibacterial treatment as soon as possible, thus reduce patient's death risk.
MRSA has already become and infected the pathogens in the highest hospital of global incidence by later stage of the eighties of last century since discovering in 1961. MRSA field planting in the human skin or nose, in the particular situation, for instance patient's immunity is low, will initiate the organism to infect with, the serious disease will even cause patient death to infect quickly, MRSA not merely infects the number of the infected more as one of the bacteria with stronger virulence on clinic, mortality is very high too, are classified as one of the infective illness most difficult to solve the whole world. "Because there can seldom be effects and is able to bear bacterial strain of medicine to this kind of in the existing traditional antibacterial medicine, the treatment that MRSA infected has been one of the clinical and very thorny difficult problems all the time. " Niederman professor introduces.
Learn a latest global result of study issued at the 48th annual meeting in U.S.A. infectious disease recently, have offered important information for treatment of pneumonia in the courtyard due to MRSA. This item global to make a definite diagnosis of first oxygen west forest able to bear the golden yellow staphylococcus of medicine (MRSA) Studying at the newest IV stage of pneumonia verifies: Mainly comment on terminal, fertile Sri Lankan (profit endures thiazole amine) Clinical therapeutic success rate is higher than through the ages mouldly and plainly, have statistics meanings. ZEPHyR (profit endures thiazole amine and treats pneumonia in the courtyard due to MRSA) It is the largest studying that is carried on in this kind of group to study up until now.
Pfizer new developing the intersection of market and Asia resist infection say by special the intersection of medicine and medical the intersection of affairs and parts of senior the intersection of director and Lin Feng Dr.: "Large-scale data of controlled study this abundant Sri Lankan fertile to treat the intersection of MRSA and evidence of pneumonia under institute, and offered for fertile therapeutic effect to this thorny disease of Sri Lankan and further accorded with. Pfizer continue, devoted to, resist infection research of field still future, clinical to resist infection to treat and offer the strong weapon constantly. "

|